You may have seen this story in Footnotes on Friday, or elsewhere as you traversed the Internet in the last several days: Deloitte will no longer be covering GLP-1 medications for weight loss and health insurance costs in general will be ratcheting up for many Green Dotters.
Business Insider was first with the scoop:
Deloitte’s US employees are joining the growing list of workers facing more expensive and less generous healthcare benefits.
The Big Four firm will no longer cover GLP-1 medication for weight-loss purposes through its medical plans, according to an internal benefits guide seen by Business Insider.
At the same time, Deloitte employees will also face higher deductibles and out-of-pocket maximums under most health plans, the document said, meaning higher costs both before and after coverage kicks in.
The communication to staff reviewed by BI said that the changes “reflect the hard trade-offs of today’s cost environment,” and that there was a need “for shared responsibility in a few specific places where it’s become untenable for Deloitte to carry the cost alone.”
As the article makes clear, the coverage change is only for those taking GLP-1s for weight loss purposes. And Deloitte isn’t the first Big 4 to do it, PwC made the same change earlier this year. A poster in r/PwC made the argument at that time that in many cases, GLP-1s “are not cosmetic or optional” even if for weight loss and rather, these medicines can be a long-term investment in employee health:
For many employees, these medications are not cosmetic or optional. They are part of medically supervised treatment for obesity, metabolic health, insulin resistance, cardiovascular risk, and other serious health conditions. Removing coverage may create a major financial barrier for people who are already working with their doctors to manage chronic health issues.
I also think this decision may be short-sighted from a business perspective. Many of us work long hours in mostly sedentary roles. If employees lose access to effective treatment, the likely result is not lower cost over time. It may mean worsening health, higher long-term claims, more complications, more missed work, and greater overall cost to both employees and the company.
It seems many employers have pulled back or plan to pull back on GLP-1 coverage as we head into 2027, so it’s not just the firms looking to pinch these particular pennies.
